KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.

Sarah C Rutherford, Hongli Li, Alex F Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K Parsons, Joseph M Unger, Anamarija M Perry, Carla Casulo, Nancy L Bartlett, Joseph M Tuscano, Brian T Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y Song, Sharon M Castellino, Brad Kahl, John P Leonard, Sonali M Smith, Jonathan W Friedberg, Andrew M Evens

J Clin Oncol 43(27) 2968-2973

PMID40523203
PMCIDPMC12353409
DOI10.1200/JCO-25-00204
发表日期2025-06-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
KM panel re-extraction failed
摘要

摘要

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three S1826 trial conducted by SWOG that randomly assigned patients with newly diagnosed advanced-stage (III-IV) cHL to six cycles of nivolumab (N)-AVD or brentuximab vedotin (BV)-AVD. Of 103 enrolled patients 60 years and older, 99 were eligible. At a median follow-up of 2.1 years, the 2-year progression-free survival was 89% after N-AVD (n = 50) and 64% after BV-AVD (n = 49, HR 0.24, 95%CI 0.09-0.63, 1-sided stratified log-rank P = .001). The 2-year OS was 96% with N-AVD versus 85% with BV-AVD (HR 0.16, 95%CI 0.03-0.75 stratified 1-sided log-rank P = .005). Six cycles were delivered without dose reduction in 69% on N-AVD and 26% on BV-AVD; 55% discontinued BV, and 14% discontinued nivolumab. The nonrelapse mortality was 16% with BV-AVD and 6% with N-AVD. Despite more neutropenia with N-AVD, febrile neutropenia, sepsis, and infections were higher with BV-AVD, as was peripheral neuropathy. Patient-reported outcomes of key adverse events confirmed the improved toxicity profile of N-AVD over BV-AVD. N-AVD was better tolerated and more effective than BV-AVD and is therefore a new standard of care for older patients with advanced-stage cHL fit for anthracycline-based combination therapy.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1A:

2-year progression-free survival (PFS) in patients ≥60 years on S1826 by arm.

2-year_PFS

PFS

Figure 1A: · Panel 2-year_PFS

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel 2-year_PFS 是同一 Figure 1A: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
No curves extracted
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1B:2-year overall survival (OS) in patients ≥60 years on S1826 by arm.
非 KM Figure
Figure 2:Odds radios for physician-rated and patient-reported Common Terminology for Adverse Events (CTCAE) on BV-AVD (reference) versus N-AVD. Key toxicities of sensory neuropathy, diarrhea, myalgia, and arthralgia occurred more frequently with BV-AVD than N-AVD in both measures. Sensory neuropathy, myalgia, and arthralgia were significantly under-reported by physicians compared to patients.
非 KM Figure